aTyr Pharma Inc
ATYR
查看详细走势图
0.899USD
+0.088+10.89%
收盘 02/06, 16:00（美东）报价延迟15分钟
88.09M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+10.89%
5天
+1.84%
1月
+20.43%
6月
-82.84%
今年开始到现在
+14.80%
1年
-76.95%
查看详细走势图
TradingKey aTyr Pharma Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
aTyr Pharma Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名75/392位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价6.36。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
aTyr Pharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
aTyr Pharma Inc亮点
亮点风险
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
业绩增长期
公司处于发展阶段，最新年度总收入235.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入235.00K美元
估值高估
公司最新PE估值-1.08，处于3年历史高位
机构减仓
最新机构持股62.14M股，环比减少0.01%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值4.96M
活跃度降低
近期活跃度降低，过去20天平均换手率1.87
分析师目标
根据
10
位分析师
持有
评级
6.357
目标均价
+621.99%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
aTyr Pharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
aTyr Pharma Inc简介
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
公司代码ATYR
公司aTyr Pharma Inc
CEOShukla (Sanjay S)
网址https://www.atyrpharma.com/
相关品种
